Phase II Study of Campath-1H Antibody to Treat Waldenstrom's Macroglobulinemia

Completed · Phase 2

Conditions studied: Lymphoplasmacytic Lymphoma, Waldenstrom's Macroglobulinemia

In brief

The purpose of this study is to determine the safety and effects (good or bad) of Campath-1H antibody in the treatment of lymphoplasmacytic lymphoma.

Key facts

Study ID

NCT00142181

Run by

Dana-Farber Cancer Institute

People needed

27

Starts

2003-03-01

Expected to finish

2008-06-01

Last updated by the study team

2012-12-21

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of lymphoplasmacytic lymphoma including patients with Waldenstrom's macroglobulinemia
• Adequate organ function: ANC > 500/ul; PLT > 25,000/ul; serum creatinine < 2.5; serum total bilirubin and SGOT < 2.5 times the upper normal limit.
• Age greater than 18 years
• Life expectancy of 6 months or greater
• ECOG performance status of 0-2

You may not qualify if…

• Chemotherapy, steroid therapy, or radiation therapy within 21 days of study entry.
• Prior Campath-1H or monoclonal antibody therapy within 3 months of study entry.
• Pregnant women
• Serious co-morbid disease, uncontrolled bacterial, fungal, or viral infection.

Where it is running

• Beth Isreal Deaconness Medical Center — Boston, Massachusetts, United States
• Dana-farber Cancer Insitiute — Boston, Massachusetts, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.